Natural Cytotoxicity Triggering Receptor 2 Proteins (NCR2)

Human Natural Cytotoxicity Triggering Receptor 2 (NCR2) interaction partners

1. We therefore identified the NKp44 binding site to PCNA and further developed an NKp44-peptide-based agent that can inhibit tumor growth through interfering with the function of intracellular PCNA in the tumor cell.

2. Increased expression of p44 natural killer cell receptor (NKp44 ) was associated earlier stages of diffuse large B-cell lymphoma (DLBCL).

3. The regulation of T cell proliferation during HPIV3 infection is mediated via NK receptors NKp44 and NKp46 and involves the surface glycoprotein haemagglutinin-neuraminidase but not the fusion protein of the virus.

4. Study identified a novel ligand for NKp44 on astrocytes. Expression of this novel ligand decreased with increasing HIV-3S peptide concentration and blocking this novel ligand decreased NK cell killing. NK cell killing of astrocytes was decreased when astrocytes were incubated with HIV-3S peptide. NKp44 has a protective effect on astrocytes from NK cell mediated killing during HIV infection and impact astrocyte's role.

5. NKp44 and NKp30 splice variants profiles are tissue/condition specific and demonstrate similarity between placenta and cancerous tissues.

6. NKp44-1 expression was significantly associated with poor survival of AML patients. Moreover, activation of PBMC from healthy controls showed co-dominant expression of NKp44-1 and NKp44-3, while primary NK clones show more diverse NKp44 splice variant profiles.

7. On CD56(+) CD3(-) cells, NKp44 and NKp46 expressions were high in the acute hepatitis E patients, whereas NKp30, NKp44, NKp46 and NKG2D were high in the recovered individuals.

8. demonstrated that the mitogen and iK562 exposure to peripheral blood mononuclear cells can significantly improve NK activity which is co-related to the higher expression of NKp44 and NKG2D

9. NCR(+) ILC3 from skin and blood of psoriasis patients produced IL-22, which is regarded as a key driver of epidermal thickening, suggesting that NCR(+) ILC3 may participate in psoriasis pathology.

10. Balance between activating NKG2D, DNAM-1, NKp44 and NKp46 and inhibitory CD94/NKG2A receptors determine natural killer degranulation towards rheumatoid arthritis synovial fibroblasts.

11. NKp44+ ILC3 are expressed in human skin and blood and may have a role in psoriasis pathogenesis

12. Expression of NKp44 ligand by normal articular chondrocytes is not involved in their killing by unstimulated NK cells; however, it is responsible for anti-chondrocyte cytotoxicity mediated by long-term activated NK cells.

13. MLL5 is a cellular ligand for the natural cytotoxicity receptor NKp44.

14. Natural killer cells in HIV controller patients express an activated effector phenotype and do not up-regulate NKp44 on IL-2 stimulation.

15. Novel interaction between proliferating cell nuclear antigen and HLA I on the surface of tumor cells inhibits NK cell function through NKp44.

16. triggering in RORgammat-positive innate lymphoid cells selectively activates a proinflammatory program

17. While interaction of TLR2 with mycobacterial cell wall promotes activation of resting NK cells and IFN-gamma production, NKp44 interaction with its putative ligands could play a secondary role in maintaining cell activation

18. Natural cytotoxicity receptors play a major role in the recognition by NK cells of cancer stem cells targets.

19. These data show that the Kaposi's sarcoma-associated herpesvirus ORF54 product downregulates the NKp44 ligand and that the NKp44-NKp44 ligand signaling pathway contributes to antiviral immunity.

20. a precise analysis of clinical data showed a correlation between decreased NCR expression and poor prognosis factors such as low haemoglobin level, high (>30x10(9) per litre) lymphocyte count or elevated C-reactive protein